Mapping the Anti-Aging Toolkit From Senolytics to Telomerase Activators
A comprehensive 2025 review charts the signaling pathways, drug targets, and emerging strategies scientists are using to slow human aging.
Summary
Researchers from China Pharmaceutical University and Nanjing University of Chinese Medicine have published a sweeping review of anti-aging therapeutics, cataloguing the key biological mechanisms driving aging alongside the most promising interventions. The review covers five major target areas: senescent cell clearance, NAD+ restoration, anti-inflammatory and antioxidant defenses, proteostasis repair, and telomerase activation. It surveys existing anti-aging compounds and emerging strategies designed to extend both lifespan and healthspan. By synthesizing decades of aging research into an organized framework of pathways and drug targets, the authors aim to guide future therapeutic development and clinical translation of interventions that could meaningfully delay age-related disease.
Detailed Summary
Aging remains one of medicine's greatest unsolved challenges, driving the majority of chronic disease burden worldwide. As the global population skews older, identifying safe and effective interventions to delay biological aging has become an urgent scientific and clinical priority. This 2025 review, published in Bioorganic & Medicinal Chemistry, provides a structured overview of where anti-aging research stands and where it is headed.
The authors systematically map the core signaling pathways and molecular targets implicated in aging. Five pillars dominate the discussion: elimination of senescent cells (senolytics and senomorphics), boosting NAD+ levels to restore mitochondrial and metabolic function, deploying anti-inflammatory and antioxidant agents to combat chronic low-grade inflammation and oxidative stress, correcting proteostasis dysfunction to prevent toxic protein aggregation, and activating telomerase to address replicative senescence.
The review catalogs advanced research on anti-aging compounds spanning these categories, including small molecules, natural products, and gene-based strategies. It highlights how multi-target approaches may outperform single-pathway interventions, given the interconnected nature of aging hallmarks.
For clinicians and researchers, the review underscores that healthspan — the period of life free from serious disease — is as important a target as raw lifespan extension. Several discussed agents are already in or approaching clinical trials, making this a timely synthesis for translational medicine.
Key caveats apply: this is a narrative review without meta-analysis, and conclusions about efficacy are largely drawn from preclinical or early-phase human data. The field also lacks standardized aging biomarkers, making it difficult to compare outcomes across studies. Nonetheless, the framework offered here provides a useful roadmap for prioritizing future drug discovery and intervention design.
Key Findings
- Five major anti-aging target areas identified: senolysis, NAD+ augmentation, antioxidant defense, proteostasis, and telomerase activation.
- Senescent cell clearance via senolytics is highlighted as a leading therapeutic strategy to reduce age-related tissue dysfunction.
- NAD+ decline is a central driver of metabolic and mitochondrial aging, making its restoration a high-priority drug target.
- Multi-pathway approaches may be necessary given the interconnected hallmarks of biological aging.
- Both lifespan and healthspan are framed as dual goals, shifting focus toward quality of life in aging intervention.
Methodology
This is a narrative literature review, not an original research study. The authors synthesized published findings on aging mechanisms and therapeutic agents across multiple databases. No meta-analytic or systematic review methodology is described in the abstract.
Study Limitations
As a narrative review, the paper may be subject to selection bias in the literature included. Efficacy claims for many agents rest on preclinical or early-phase data, limiting direct clinical application. The absence of standardized aging biomarkers across studies complicates cross-comparison of therapeutic outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.